Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rothenberg

Showing results (91-100 of 162) with videos related to

Pageof 17
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
New anticancer agentsC Britten, L Hammond, M Hidalgo, et al.
Head & Neck|July 24, 2010
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinomaChristine H Chung, Paula R Pohlmann, Mace L Rothenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinomaC D Blanke, D G Haller, A B Benson, et al.
The New England Journal of Medicine|March 23, 2017
Advantages of a Truly Open-Access Data-Sharing ModelMonica M Bertagnolli, Oliver Sartor, Bruce A Chabner, et al.
Diabetes, Obesity & Metabolism|February 21, 2012
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetesL B Katz, J J Gambale, P L Rothenberg, et al.
Investigational New Drugs|August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumorsAndrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
American Journal of Clinical Oncology|February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumorsA Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
American Journal of Clinical Oncology|January 11, 2011
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancerEmily Chan, Bonnie Lafleur, Mace L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancerRichard M Goldberg, Isabelle Tabah-Fisch, Harry Bleiberg, et al.
Cancer|November 7, 1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancerJ D Shapiro, M L Rothenberg, G A Sarosy, et al.
Pageof 17

Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
New anticancer agentsC Britten, L Hammond, M Hidalgo, et al.
Head & Neck|July 24, 2010
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinomaChristine H Chung, Paula R Pohlmann, Mace L Rothenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinomaC D Blanke, D G Haller, A B Benson, et al.
The New England Journal of Medicine|March 23, 2017
Advantages of a Truly Open-Access Data-Sharing ModelMonica M Bertagnolli, Oliver Sartor, Bruce A Chabner, et al.
Diabetes, Obesity & Metabolism|February 21, 2012
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetesL B Katz, J J Gambale, P L Rothenberg, et al.
Investigational New Drugs|August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumorsAndrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
American Journal of Clinical Oncology|February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumorsA Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
American Journal of Clinical Oncology|January 11, 2011
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancerEmily Chan, Bonnie Lafleur, Mace L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancerRichard M Goldberg, Isabelle Tabah-Fisch, Harry Bleiberg, et al.
Cancer|November 7, 1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancerJ D Shapiro, M L Rothenberg, G A Sarosy, et al.
Pageof 17